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Background aims. Mesenchymal stromal cell (MSC) delivery of pro-apoptotic tumor necrosis factor (TNF)-related
apoptosis-inducing ligand (TRAIL) is an attractive strategy for anticancer therapy. MSCs expressing full-length human
TRAIL (ﬂT) or its soluble form (sT) have previously been shown to be effective for cancer killing. However, a comparison
between the two forms has never been performed, leaving it unclear which approach is most effective. This study addresses
the issue for the possible clinical application of TRAIL-expressing MSCs in the future.Methods.MSCs were transduced with
lentiviruses expressing ﬂT or an isoleucine zipper-fused sT. TRAIL expression was examined and cancer cell apoptosis was
measured after treatment with transduced MSCs or with MSC-derived soluble TRAIL. Results. The transduction does not
adversely affect cell phenotype. The sT-transduced MSCs (MSC-sT) secrete abundant levels of soluble TRAIL but do not
present the protein on the cell surface. Interestingly, the ﬂT-transduced MSCs (MSC-ﬂT) not only express cell-surface
TRAIL but also release ﬂT into medium. These cells were examined for inducing apoptosis in 20 cancer cell lines.
MSC-sT cells showed very limited effects. By contrast, MSC-ﬂT cells demonstrated high cancer cell-killing efﬁciency. More
importantly, MSC-ﬂT cells can overcome some cancer cell resistance to recombinant TRAIL. In addition, both cell surface
ﬂT and secreted ﬂT are functional for inducing apoptosis. The secreted ﬂT was found to have higher cancer cell-killing
capacity than either recombinant TRAIL or MSC-secreted sT. Conclusions. These observations demonstrate that MSC
delivery of ﬂT is superior to MSC delivery of sT for cancer therapy.
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Cancers are one of the leading causes of human
death in the world. Each year, more than 10 million
new cases of cancer occur globally. Current treat-
ments for metastatic cancers including chemother-
apies or radiotherapies often provide limited beneﬁts
to patients and are frequently accompanied by
undesired side effects. Novel therapies are needed.
Tumor necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL) is a promising agent for
cancer therapy. TRAIL is a type II transmembrane
protein with homology to other members in the TNF
family [1,2], and it selectively triggers apoptosis in
tumor cells while sparing normal cells [1e3]. It is
safe to deliver, with the ligand exhibiting no detect-
able cytotoxicity to normal tissues in murine and
primate models [4,5] or in humans [6]. AgonistCorrespondence: Sam M. Janes, MD, PhD, Lungs for Living Research Centr
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Rs) have also been used in phase II clinical trials and
have shown good safety and tolerability [5,7,8].
However, the enthusiasm in developing TRAIL as a
novel cancer therapeutic has been tempered by the
challenges of recombinant TRAIL’s short half-life
(w30 min), limited bioavailability and poor phar-
macokinetics. The clinical trials of recombinant sol-
uble TRAIL and agonistic TRAIL-R antibodies have
thus far shown limited therapeutic beneﬁt [9].
We and others have used mesenchymal stromal
cells (MSCs) as a vector to target TRAIL therapy
directly to tumor metastases [10e13]. MSCs prefer-
entially migrate to and incorporate within tumors and
their metastases-forming tumor stroma [10,14e18].
Several groups, including our own, have demonstrated
that intravenously delivered MSCs preferentiallye, Division of Medicine, Rayne Building, 5 University Street, WC1E 6JF
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886 Z. Yuan et al.localize in lung, breast and melanoma lung metas-
tases [10,19,20], Kaposi’s sarcoma [21], colorectal
cancer [22] and glioma [23]. MSC tumor tropism
has also been demonstrated after intraperitoneal
delivery of MSCs for ovarian cancer [24] and
intracerebral delivery of MSCs in a glioma model
[25].
MSC-delivered targeted TRAIL overcomes the
limited half-life of systemically delivered recombi-
nant TRAIL. In murine models, we have shown that
systemic injection of MSCs expressing full-length
human TRAIL leads to a reduction in subcutane-
ous tumor growth and reduced, or indeed elimi-
nated, lung metastases [10], and attenuates
malignant pleural mesothelioma development [13].
Others have shown that MSCs engineered to express
soluble TRAIL are able to kill cancer cells both
in vitro and in vivo [26,27]. MSCs expressing soluble
TRAIL may have an advantage in vivo in secreting
TRAIL throughout the tumor rather than relying on
the cell-cell contact that is required by the
membrane-bound full-length TRAIL expressed on
the MSC surface. In our preclinical development of
MSC TRAIL therapy work, we wished to deﬁne the
relative sensitivity of cancer cells to the different
TRAIL forms expressed from a clinically approved
lentiviral backbone. To elucidate which strategy is
optimal, we created MSCs expressing full-length or
soluble TRAIL and compared their activity in
inducing cancer cell apoptosis.Methods
Cell culture
Cell culture reagents were purchased from Invi-
trogen unless otherwise stated. Twenty cancer cell
lines were used, including six lung cancer lines,
A549, NCI-H460, NCI-H727, NCI-H23, H226 and
PC9; seven malignant pleural mesothelioma lines,
NCI-H2052, H2795, H2804, H2731, H2810,
H2452 and H2869; three colon cancer lines,
Colo205, HT29 and RKO; two renal cancer lines,
RCC10 and HA7-RCC; one human oral squamous
cell carcinoma line, H357; and one human breast
adenocarcinoma line, MDAMB231 (M231). A549,
H357 and M231 were obtained from Cancer
Research United Kingdom. Other cell lines were
kind gifts from Dr Ultan McDermott of the Well-
come Trust Sanger Institute, Cambridge, United
Kingdom. NCI-H23, HT29 and Colo205 cells were
cultured in Roswell Park Memorial Institutee1640
medium with 10% fetal bovine serum (FBS); RKO
cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM)/F-12 with 10% FBS; H357 cells
were cultured in DMEM/F-12 (3:1) supplementedwith 0.5 mg/mL hydrocortisone and 1010 mol/L
cholera toxin (Sigma-Aldrich), 10 ng/mL epithelial
growth factor (Cambridge Biosciences) and 5 mg/mL
human insulin (MP Biomedicals); all other cell lines
were grown in the DMEM containing 10% FBS.
Well-characterized human adult MSCs (passage 1)
were purchased from the Texas A&M Health
Science Center and cultured in the a-minimum
essential medium containing 17% FBS.Construction of TRAIL vectors
The construction of the lentiviral vectors for the
expression of ﬂT and its soluble form (sT) was based
on the lentiviral plasmid pCCL-c-Fes-Gfp [28]. The
promoter of the backbone plasmid was replaced by
the cytomegalovirus (CMV) promoter/enhancer [29]
at XhoI and BamHI restriction sites. The CMV
promoter/enhancer was ampliﬁed by means of poly-
merase chain reaction (PCR) with the use of the
pCMVedR8.74 plasmid as a template (a kind gift
from Dr Thrasher, University College London). To
create the ﬂT vector, the ﬂT-encoding complemen-
tary DNA (cDNA) was ampliﬁed by means of PCR
with the use of our previously constructed inducible
ﬂT plasmid [10] as a template and inserted into the
backbone in place of the green ﬂuorescent protein
(GFP) sequence through the use of BamHI and SalI
sites; the resulting new plasmid is designated pCCL-
CMV-ﬂT. To create the sT vector, an open reading
frame encoding an N-terminaletruncated extracel-
lular portion of human TRAIL (amino acids
95e281) was ampliﬁed by means of PCR, which was
then used as template for sequential PCRs to fuse the
isoleucine zipper (IZ) (MKQIEDKIEEILSKIY
HIENEIARIKKLIGERE) [30] in-frame and the
murine immunoglobulin L-chain (IgL; 50-ATGG
AGACAGACACACTCCTGCTATGGGTACTG
CTGCTCTGGGTTCCAGGTTCCACTGGTGA
C-30) leader sequence [31] to its N-terminal. The
obtained sT sequence was inserted into the
pCCL-CMV-ﬂT in place of ﬂT through the BamHI
and SalI sites, creating the sT vector designated
pCCL-CMV-sT.Lentivirus preparation and transduction of MSCs
The lentivirus supernatants were produced by
co-transfection of 293T cells with construct plasmids
together with the packaging plasmids pCMV-dR8.74
and pMD2.G in the presence of a DNA transfection
reagent jetPEI (Source Bioscience UK Ltd). The
pMD2.G and pCMV-dR8.74 plasmids were kindly
provided by Dr Thrasher, University College
London (UCL). Lentiviruses in supernatants were
concentrated by ultracentrifugation at 17,000 rpm
MSC delivery of TRAIL for cancer therapy 887(SW28 rotor, Optima LE80K Ultracentrifuge,
Beckman) for 2 h at 4C. Human MSCs were
transduced with a multiplicity of infection (MOI) of
2 and 8 mg/mL polybrene (Sigma-Aldrich). Human
TRAIL expression was veriﬁed by means of an
enzyme-linked immunoassay (ELISA) (R&D Sys-
tems) according to the manufacturer’s instructions
and by Western blot analysis.Flow cytometry of lentivirus-transduced cells
To determine the titers of prepared lentiviruses,
293T cells were transduced with serial dilutions of
viruses in the presence of 8 mg/mL polybrene. After
3 days, TRAIL or GFP expression was examined by
means of ﬂow cytometry. For ﬂow cytometry detec-
tion of TRAIL expression, cells were stained with a
1:10 dilution of phycoerythrin (PE)-conjugated
mouse monoclonal antibody against human TRAIL
(Ab47230, Abcam).MSC phenotyping and differentiation assay
MSC phenotyping was carried out by use of the human
MSC Phenotyping Kit (Miltenyi Biotec, Cat. No.
130e095e198) according to the manufacturer’s in-
structions, and cells were analyzed by means of ﬂow
cytometry. Differentiation of passage 7 MSCs with or
without transduction was performed by use of the
StemPro Chondrogenesis, Osteogenesis or Adipo-
genesis Differentiation Kits (GIBCO Invitrogen Cell
Culture). Adipocytes were stained with high content
screening LipidTOX green and 40-6-diamidino-2-
phenylindole (DAPI), osteocytes were stained with
alizarin red S and the chondrogenic pellet was stained
with alcian blue, all according to the manufacturer’s
instructions. In addition, to quantitatively compare
the differentiation potential of transduced MSCs
with untransduced parental cells, MSCs and MSC-
ﬂT cells with or without induction of adipogenesis
differentiation for 10 days or with/without induction
of osteogenesis for 13 days were analyzed for dif-
ferentiation marker gene expression by means of
real-time quantitative PCR. In brief, total cellular
RNAs were extracted and reverse-transcribed into
cDNAs, followed by real-time PCR analysis with
the use of SYBR green PCR Master Mix (AB Inc,
P/N 4367659) according to the manufacturer’s
instructions. The previously validated MSC adipo-
genesis marker gene PPARG [32] and osteogenesis
gene BMP2 [33] were examined for their messenger
RNA expression changes by use of the commonly
used reference gene RPL13A for normalization,
which has been validated as suitable for real-time
quantitative PCR of bone-marrowederived MSCs
[34]. Primers were purchased for PPARG (AccessionNo. NM-015869/Cat. No. HP226175, OriGene
Technologies), BMP2 (NM_001200/HP205130) and
RPL13A (NM_012423/HP210356).Data analysis was
performed by use of the previously described 2DDCt
method [35].Cell proliferation assays
Assessment of cell proliferation and viability was
determined with the use of the XTT Cell Prolifera-
tion Assay Kit, according to the manufacturer’s
instructions; 10,000 passage 7 MSCs were seeded
per well of a 24-well plate, and the assay was per-
formed in triplicate every 24 h for a total of 7 days.Western blot analysis
Passage 4 or 5 MSCs were harvested and lysed
in radio-immunoprecipitation buffer (phosphate-
buffered saline, 1% Igepal Ca-630, 0.5% sodium
deoxycholate and 0.1% sodium dodecyl sulfate
[Sigma]) supplemented with complete protease in-
hibitor cocktail (Complete-mini; Roche Diagnostics);
10mg of protein from thewhole-cell lysates and 5mLof
50-foldeconcentrated culture supernatant were pre-
pared, resolved on 4% to 12% polyacrylamide sodium
dodecyl sulfate gels and analyzed by means of
immunoblotting with rabbit anti-human TRAIL
(c-terminal) Ab (ab42121, Abcam) and antiea-
tubulin Ab (11H10, Cell Signalling), respectively.Immunoﬂuorescence
Localization of TRAIL in cells was examined bymeans
of immunoﬂuorescence staining. For intracellular
staining, cells were grown on chamber slides for 2 days,
ﬁxed with 4% paraformaldehyde, permeabilized in
0.1%saponin-containingbuffer, blocked inphosphate-
buffered saline containing 10%FBS and 0.1% saponin
and then stained with the PE-conjugated mouse
anti-human TRAIL monoclonal antibody B-S23
(Abcam, Cat. No. ab47230). The counterstain Alexa-
488econjugated phalloidin (Life Technologies) was
also added for labeling ﬁlamentous actin (F-actin). For
cell-surface TRAIL labeling, cells were stained with
PE-conjugated anti-TRAIL Ab after ﬁxation and
blocking but before permeabilization and F-actin
counterstaining. Stained cells were mounted with the
ProLong Gold Antifade Reagent with DAPI
(Invitrogen), viewed and imaged by confocal micro-
scopy (Leica TCS SP2 microscope).Supernatant TRAIL preparation
Two million transduced MSCs were cultured in one
T175 ﬂask for 3 days with 20 mL of media. Proteins
888 Z. Yuan et al.were concentrated 50-fold through the use of the
centrifugal concentration column (Millipore
UFC901008, MWCO 10 kDa). TRAIL levels in
concentrated media were determined with the use of
the TRAIL quantiﬁcation ELISA kit (R&D
Systems).Co-culture and apoptosis analysis
DiI-labeled cancer cells (n ¼ 8000) were plated into
one well of a 96-well plate, to which transduced
MSCs, puriﬁed recombinant TRAIL 50 ng/mL
(amino acids 114e281) (Peprotech), the pan-caspase
inhibitor Z-VAD-FMK (1 mg/mL [Sigma]), a
neutralizing monoclonal anti-TRAIL Ab (10 ng/mL
[Sigma, Cat. No. T3067]) or control medium was
added for 24 h. Ratios of MSCs to cancer cells
included 1:10, 2:10, 4:10, 6:10, 8:10 and 10:10
(MSC: cancer cell). Floating and adherent cells were
stained with AF647-conjugated Annexin V (Invi-
trogen) and 2 mg/mL DAPI (Sigma) and were
assessed by means of ﬂow cytometry. Annexin Vþ
cells were considered to have undergone apoptosis;
Annexin Vþ/DAPIþ cells were considered to be
dead by apoptosis.Active caspase-8 staining
Cancer cells were DiO-labeled according to the
manufacturer’s instructions, before being treated
for 24 h with MSCs expressing TRAIL or GFP to
induce apoptosis. The treated cells were harvested,
stained with the active caspase-8 inhibitor
IETD-FMK-conjugated to sulfo-rhodamine (Bio-
Vision, K198-25) according to the manufacturer’s
instructions and analyzed by means of ﬂow
cytometry.Statistical analysis
Data were analyzed with the use of GraphPad Prism
6 software (GraphPad Software) and Mastercycler ep
realplex software version 2.2. Statistical signiﬁcance
between groups was determined by use of the Stu-
dent’s t-test. Signiﬁcant probability values are
denoted as P < 0.05, P < 0.01.Results
Construction of lentiviral vectors and TRAIL expression
The lentiviral plasmid pCCL-c-Fes-Gfp [28] was
used to construct two lentiviral vectors, pCCL-CMV-
ﬂT (full-length human TRAIL) and pCCL-CMV-sT
(truncated soluble TRAIL). The c-Fes promoter in
the backbone vector was replaced by a CMVpromoter/enhancer to give constitutive and high
expression of proteins of interest. For the ﬂT
construct, the GFP sequence was replaced with
human TRAIL (amino acids 1e281). The soluble
TRAIL vector was made by fusing in-frame DNA
sequences (from 50 to 30), including a leader sequence
frommurine immunoglobulinL-chain (IgL leader) to
assist secretion, an IZ to enhance trimerization and
amino acids 95e281 of human TRAIL (Figure 1A).
TRAIL lentiviruses were prepared by transfecting
293T cells with TRAIL constructs together with
packing plasmids.
Well-characterized human adult MSCs were
purchased from the Texas A&M Health Science
Center and were shown to be able to differentiate
into chondrogenic, osteogenic and adipogenic lin-
eages. TRAIL-transduced MSCs (MOI 2) were
examined by ﬂow cytometry with the use of a
PE-conjugated anti-human TRAIL antibody, which
demonstrated that more than 98% of ﬂT-
transduced MSCs (MSC-ﬂT) were positive for
TRAIL expression, whereas only approximately 1%
of control GFP virus-infected cells were positive,
which indicated TRAIL expression was not the
result of endogenous TRAIL induction after lenti-
virus infection (Figure 1B). In addition, more than
97% of soluble TRAIL-transduced MSCs (MSC-
sT) were positive for TRAIL expression
(Figure 1B). Of note, full-length TRAIL expression
was stable through passages 4e8, but expression of
soluble TRAIL decreased by just under 20% during
this time (Figure 1C). All further MSC TRAIL
comparison experiments were carried out in pas-
sage 4 or 5 cells.
To further assess MSC TRAIL expression,
immunoblot analysis of cellular lysates was carried
out. Both MSC-ﬂT and MSC-sT cells expressed
abundant cellular TRAIL proteins with similar
expression levels, whereas GFP-transduced MSCs
showed no detectable TRAIL expression
(Figure 1D). The MSC-ﬂT lysate showed a TRAIL
band of w32 kDa and the MSC-sT lysate showed a
band of w27 kDa, which was larger than its pre-
dicted size of 24 kDa, possibly as a result of the
glycosylation of the ligand [1]. Secreted TRAIL
protein was detected in supernatants of both
MSC-sT and MSC-ﬂT cells but not in that of
GFP-transduced cells (Figure 1E). The MSC-sT
cells secreted abundant soluble TRAIL of
w27 kDa and w24 kDa size. Three soluble TRAIL
molecular forms were detected in the supernatant of
MSC-ﬂT cells, that of w35 kDa and w32 kDa,
corresponding to the glycosylated and non-
glycosylated full-length TRAIL, and that of
w24 kDa, corresponding to a cleaved form
(Figure 1D) [36].
Figure 1. Expression of recombinant TRAIL by transduced MSCs. (A) Schematic description of TRAIL expression constructs.
(B) Fluorescence-activated cell sorting analysis of lentivirus-transduced MSCs. (C) Long-term ﬂuorescence-activated cell sorting analysis of
TRAIL expression in MSCs transduced at passage 3 (p3), expanded and passaged every 7 days until p8. (D) Detection of TRAIL and
a-tubulin expression by immunoblotting. Cont. represents MSC-GFP cell lysates or supernatant medium; ﬂT and sT represent cell lysates
or concentrated culture supernatant from MSC-ﬂT and MSC-sT cells, respectively; rT represents 1 ng of puriﬁed recombinant human
TRAIL (amino acids 114e281) produced from bacterial cells (PeproTech). (E) Levels of TRAIL in cell culture supernatants from MSCs
transduced at p3 and expanded for one passage, measured by ELISA. Data presented as TRAIL released by 1 million cells per hour (ng/h/
1  106 cells). Data represent averages  SEM (n ¼ 5).
MSC delivery of TRAIL for cancer therapy 889To assess the rate of TRAIL secretion, a highly
speciﬁc sandwich ELISA was used to quantify solu-
ble TRAIL in MSC supernatant medium. MSC-sT
cells secrete high levels of soluble TRAIL at a rate
of 3.63  0.71 ng/h for every 1 million cells
(Figure 1E). Interestingly, MSC-ﬂT cells secrete
1.3  0.52 ng/h soluble TRAIL for every 1 million
cells. MSC-GFP cells did not secrete measurable
TRAIL (Figure 1D, E).
To examine the cellular distribution of TRAIL
in transduced MSCs, immunolabeling of the
ligand was performed with the use of a
PE-conjugated anti-TRAIL antibody. As shown in
Figure 2, positive staining of TRAIL was observed
in both MSC-ﬂT and MSC-sT cells but not in
parental untransduced cells. Fluorescence
microscopy revealed that TRAIL distribution is
exclusively cytoplasmic in MSC-sT cells, whereasMSC-ﬂT cells show both cell-surface and intra-
cellular TRAIL expression. Interestingly, TRAIL
labeling in MSC-ﬂT cells appeared to be enriched
at the leading edge of lamellipodia and tips of
ﬁlopodia (Figure 2, inset).MSC viability, protein expression and differentiation are
not affected by TRAIL-expressing lentiviral infection
TRAIL-transduced MSCs were analyzed for
changes in phenotype after lentiviral infection.
MSC-sT and MSC-ﬂT cells demonstrated viability
and proliferation rates that were equivalent to non-
transduced cells (Figure 3A). Expression of the
characteristic MSC markers CD105, CD90 and
CD73 (Figure 3B) and lack of expression of the
haematopoietic markers CD14, CD20, CD34 and
CD45 (not shown) was unchanged by
Figure 2. Immunoﬂuorescent detection of recombinant TRAIL (red) expressed by transduced MSCs. Phalloidin staining was used to show
ﬁlamentous actin (green); nuclei were labeled with DAPI (blue). Top panel shows intracellular staining; bottom panel shows cell surface
staining. Images are representative of at least three experiments for each staining condition. Magniﬁcation 400.
890 Z. Yuan et al.transduction. Differentiation potential of lentivir-
ally infected cells was also unaltered compared with
parent untransduced cells, with both cell types
showing similar transcriptional expression in-
creases of the adipogenesis marker gene PPARG
and the osteogenesis marker gene BMP2
(Figure 3C) as well as equivalent adipogenic,
osteogenic and chondrogenic differentiationFigure 3. TRAIL expression by lentiviral transduction does not affect MS
potential. (A) Cell viability and proliferation were assessed with the use o
cultured MSCs for expression of conventional MSC markers is shown. D
speciﬁc antibody staining (red, MSC; blue, MSC-ﬂT; green, MSC-sT). (C
quantitative PCR for adipogenic marker gene PPARG and osteogenic
immunochemistry. (D) High content screening lipidTOX green staining (
adipogenic differentiation; middle, alizarin red S staining (red) to show o
chondrogenic differentiation. Magniﬁcation 200 for adipogenesis and ocapacities (MSC-ﬂT shown in Figure 3D) after
differentiation induction.MSC-ﬂT cells induce greater apoptosis in cancer cells
than MSC-sT cells
In Figure 1E, we demonstrate that both MSC-sT and
MSC-ﬂT cells secrete TRAIL into their cultureC viability, proliferation, marker protein expression or differentiation
f the XTT assay for 7 days after transduction. (B) Phenotyping of
ashed line shows isotype antibody control; solid line shows marker-
) MSC differentiation potential was assessed by means of real-time
gene BMP2 before and after differentiation period (Differ.) and
green) for neutral lipid and DAPI staining for nuclei (blue) to show
steogenic differentiation; right, alcian blue staining (blue) to show
steogenesis assays; magniﬁcation 50 for chondrogenesis assay.
Figure 4. MSCs expressing TRAIL induce apoptosis in cancer cells. (A, B) Cancer cell apoptosis was measured by means of ﬂow cytometry
24 h after co-culturing the breast adenocarcinoma cells MDAMB231 (M231) (A) or the lung adenocarcinoma cells A549 (B) with
MSC-GFP, MSC-ﬂT or MSC-sT cells, with an increasing ratio of MSCs to cancer cells in the co-culture system. (C) Activated caspase-8
levels in A549 cells were measured by means of ﬂow cytometry after co-culture with MSC-GFP, MSC-sT or MSC-ﬂT cells at a ratio of 4:10
(MSC: cancer cell). (D) MSC-ﬂTeinduced cancer cell apoptosis can be blocked by the 20 mmol/L pan-caspase inhibitor Z-VAD-FMK
(zVAD) and 100 ng/mL TRAIL-neutralizing monoclonal Ab (T3067, Sigma-Aldrich). Data represent averages  SEM. **P < 0.01
compared with MSC-ﬂT co-culture by Student’s t-test.
MSC delivery of TRAIL for cancer therapy 891medium. However, the level of TRAIL that is
secreted by MSC-sT cells is higher than that secreted
by MSC-ﬂT cells, which indicates that these cells may
have higher cancer cell-killing efﬁciency. To test this,
we examined cancer cell apoptosis in co-culture ex-
periments with MSC-sT and MSC-ﬂT cells. We
initially examined killing of the known TRAIL-
sensitive MDAMB231 (M231) cell line and then
tested the TRAIL-resistant lung cancer line, A549.
M231 cells were co-cultured with MSC-sT,
MSC-ﬂT or MSC-GFP cells at ratios of increasing
numbers ofMSCs to cancer cells, ranging from1:10 to
1:1 (MSC: cancer cell). Apoptosis was measured by
use of DAPI and Annexin V labeling by means of ﬂow
cytometry. As shown in Figure 4A, bothMSC-sT and
MSC-ﬂT cells induced M231 apoptosis in a dose-
dependent manner; however, MSC-ﬂT cells were
more efﬁcient than were MSC-sT cells at inducing
apoptosis (Figure 4A). At all co-culture cell number
ratios, MSC-ﬂT cells showed higher killing capacity
than did MSC-sT cells. Similarly, A549 cells
demonstrated greater cell death when co-cultured
with MSC-ﬂT cells compared with MSC-sT cells
(Figure 4B). TRAIL-induced apoptosis involves
caspase-8 recruitment and activation [37]. Thus, we
next analyzed the activated caspase-8 levels in
co-cultured cancer cells by means of ﬂow cytometry.
The A549 cells showed increased caspase-8 activation
when co-cultured withMSC-ﬂT cells at a ratio of 4:10
(MSC: cancer cell) but not when cultured withMSC-sT cells or with MSC-GFP cells (Figure 4C).
This is consistent with the relative cancer cell
apoptosis rates (Figure 4B). To further conﬁrm
apoptotic pathway activation by TRAIL-expressing
MSCs, the caspase inhibitor Z-VAD-FMK and the
anti-TRAIL antibody T3067 were added toMSC-ﬂT
cell co-cultures. These experiments demonstrated
that MSC-ﬂT killing is caspase-dependent and re-
quires TRAIL receptor activation (Figure 4D).MSC-ﬂT cells partly overcome TRAIL resistance of
cancer cells
To determine if the higher cancer cell-killing capacity
exerted by MSC-ﬂT cells compared with MSC-sT
cells is more broadly applicable, we extended our
co-culture assay to a panel of 20 established cancer cell
lines.Thepanel included six cancer types consisting of
six lung cancer lines, A549, NCI-H460, NCI-H727,
NCI-H23, H-226 and PC9; seven malignant meso-
thelioma lines, NCI-H2052, H2795, H2804, H2731,
H2810, H2452 and H2869; three colon cancer lines,
Colo205, HT29 and RKO; two renal cancer lines,
RCC10 and HA7-RCC; one human oral squamous
cell carcinoma line, H357; and one breast cancer line,
MDAMB231.
The 20 cancer cell lines were also treated with
recombinant TRAIL (rTRAIL) at a concentration of
50 ng/mL or with control GFP-transduced MSCs.
Control MSCs did not induce cancer cell apoptosis.
Figure 5. MSC-ﬂT cells induce cancer cell apoptosis with a higher efﬁciency than MSC-sT cells. (AeD) Apoptosis of ﬁve highly TRAIL-
sensitive cancer cell lines, Colo205, NCI-H460, H727, H2795 and H2804 (A); ﬁve moderately TRAIL-sensitive cancer cell lines, H2731,
H226, H2869, PC9 and M231 (B); four cancer cell lines of low TRAIL sensitivity, HT29, H357, H2452 and RKO (C); and six TRAIL-
resistant cancer cell lines, A549, NCI-H2052, H2810, NCI-H23, RCC10 and HA7-RCC (D) was determined after 24 h of culture with
medium (control), 50 ng/mL of puriﬁed recombinant TRAIL (rTRAIL), MSC-GFP, MSC-ﬂT or MSC-sT, with a ratio of 4 p4 MSC to 10
cancer cells. Data represent averages of three experiments with triplicate repeats for each cell line.
892 Z. Yuan et al.After rTRAIL treatment, the 20 cell lines showed a
varied response and were grouped accordingly into
those that were rTRAIL-sensitive (apoptosis 70%;
ﬁve cell lines), those that were moderately TRAIL-
sensitive (apoptosis 35% to 70%; ﬁve cell lines),
those that showed low TRAIL sensitivity (apoptosis
20% to 35%; four cell lines) or those that were
TRAIL-resistant (apoptosis 20%; six cell lines)
(Figure 5AeD). Control MSC-GFP, MSC-ﬂT and
MSC-sT cells were applied to cancer cells with a
ratio of 4:10 (MSC: cancer cell). For all four cancer
cell groups, MSC-sT cells showed only marginal
effects on apoptosis induction, whereas MSC-ﬂT
cells demonstrated effective killing of cancer cells
(Figure 5AeD). Of note, in the highly TRAIL-
sensitive group, MSC-ﬂT cells exerted a similar
level of cancer cell killing to 50 ng/mL rTRAIL; for
moderate and low TRAIL-sensitive and TRAIL-
resistant groups, MSC-ﬂT cells induced more
apoptosis than did rTRAIL.Soluble TRAIL released by MSC-ﬂT cells is of higher
activity than rTRAIL and sT
Unexpectedly, MSC-sT and MSC-ﬂT cells both
release abundant TRAIL into the supernatant
medium (Figure 1E). We had anticipated that thetruncated soluble form of TRAIL that is secreted by
MSC-sT cells would have pro-apoptotic effects on
nearby cancer cells. Having found that MSC-ﬂT
cells not only express full-length TRAIL on their
cell surface but also secrete full-length TRAIL into
the culture medium, we tested the relative killing
efﬁcacy of both the full-length and the truncated
secreted forms of TRAIL.
To obtain sufﬁcient amounts of soluble TRAIL,
supernatant media were collected from cultured
MSC-ﬂT and MSC-sT cells under low serum con-
ditions (1% FBS), ﬁltered through 0.2-mm ﬁlters and
concentrated 50-fold with centrifugal columns (10
kDa). Supernatant medium from GFP-transduced
MSCs was also collected and concentrated and
used as a control. ELISA quantiﬁcation showed that
the concentrated MSC-ﬂT supernatant medium
contained 0.4  0.2 mg/mL of TRAIL and that the
MSC-sT supernatant medium contained 1.2  0.3
mg/mL TRAIL.
Primary human lung bronchial epithelial cells and
two cancer cell lines, M231 and A549, were treated
with the supernatant preparations of ﬂT or sT,
rTRAIL or control medium to compare cytotoxicity.
Human lung bronchial epithelial cells showed com-
plete resistance to all three TRAIL preparations
(data not shown). By contrast, M231 cells, which are
Figure 6. MSC-ﬂTederived cell surface and secreted TRAILs
contribute to induction of apoptosis in cancer cells. (A, B)
Apoptosis was measured by means of ﬂow cytometry after expo-
sure of M231 cells (A) or A549 cells (B) for 24 h to increasing
doses of recombinant TRAIL (rTRAIL), supernatant TRAIL
from MSC-sT (sTRAIL) or supernatant TRAIL from MSC-ﬂT
(ﬂTRAIL). (C) Apoptosis was measured after 24-h co-culture of
A549 cells with live or ﬁxed MSC-GFP and MSC-ﬂT cells,
respectively. Data represent averages  SEM (n ¼ 3). *P < 0.05,
**P < 0.01 compared with rTRAIL and MSC-GFP treatment,
respectively, by Student’s t-test.
MSC delivery of TRAIL for cancer therapy 893a moderate TRAIL-sensitive cancer cell line, showed
dose-dependent sensitivity to all three TRAIL forms
(Figure 6A). As expected, as a result of our insertion
of the trimerization domain IZ, sT showed higher
cytotoxicity than did rTRAIL; however, interest-
ingly, ﬂT induced most apoptosis (Figure 6A). Of
particular note, ﬂT was capable of inducing
apoptosis in rTRAIL-resistant A549 cells, but sT was
not capable (Figure 6B).Cell-surface TRAIL on MSC-ﬂT cells contributes to
apoptosis induction
To conﬁrm the role of cell-surface TRAIL expres-
sion in the induction of apoptosis, we ﬁxed
MSC-ﬂT cells with 4% paraformaldehyde to stop
TRAIL secretion into the supernatant and thenco-cultured them with A549 cells. Whereas ﬁxed-
control MSC-GFP cells did not show any cancer
cell killing, the ﬁxed MSC-ﬂT cells demonstrated
signiﬁcant killing of cancer cells (Figure 6C).
TRAIL ELISA conﬁrmed no detectable TRAIL
release in the supernatant of ﬁxed MSC-ﬂT cells.
Therefore, the induction of apoptosis by MSC-ﬂT
cells is at least partially due to the TRAIL
expressed on the cell surface. MSC-sT cells were
also ﬁxed and tested for A549 killing but failed to
show any cancer cell killing (data not shown),
which is consistent with the fact that MSC-sT cells
do not express cell-surface TRAIL (Figure 2).Discussion
We have previously shown that MSCs expressing full-
length TRAIL can signiﬁcantly reduce, and in some
cases eliminate, lung metastases in a murine model
[10]. In these previous experiments, we used the
pRRL-derived self-inactivating lentiviral backbone
[38], into which the TRAIL-encoding cDNA and
IRES-eGFP reporter sequence were sequentially
introduced, under the control of the tetracycline-
regulated CMV minimal promoter [10]. To produce
a clinically relevant therapeutic, in this study we
subcloned soluble or full-length TRAIL and CMV
promoter/enhancer into the MHRA humane
approved lentiviral vector pCCL-c-Fes-Gfp (30).
The new vectors that we created use the constitutive
CMV promoter and do not contain the tet-on condi-
tional system.We then compared the killing efﬁciency
of full-length TRAIL with soluble TRAIL, with the
hypothesis that secreted TRAIL may improve
efﬁciency.
In the present study, we have shown that MSC
infection with the new lentiviruses expressing the
different TRAIL forms does not affect MSC differ-
entiation capacity or cell proliferation. We demon-
strate that full-length TRAIL is indeed expressed at
the cell membrane, in contrast to the cytoplasmic
expression of soluble TRAIL. Intriguingly, both
soluble and full-length TRAIL are secreted (although
soluble TRAIL is secreted at greater levels), which
removes some of the potential beneﬁt of the use of a
soluble TRAIL to treat an in vivo tumor in which
TRAIL diffusion through the tumor could enhance
anti-cancer activity. Most importantly, we show that
cellular presentation of the full-length form of TRAIL
is superior in cancer cell killing to the cellular pro-
duction of the soluble form of TRAIL.
MSCs have been successfully used to deliver
several gene therapies to tumors in murine models.
Cytokines and chemokines such as interleukin-2
(IL-2) [39], IL-12 [40], CX3CL1 [20] and
interferon-b [19,41e43] have been shown to be
894 Z. Yuan et al.therapeutically beneﬁcial when delivered by MSCs.
In addition, MSCs were successfully used to deliver
oncolytic virus [22,44]. MSCs have also been engi-
neered to express an enzyme that converts a pro-drug
into a cytotoxic agent at the site of tumors [45,46].
MSCs engineered to express TRAIL have shown
therapeutic effects in mouse lung metastasis [10,11]
and glioma [12] models. We recently demonstrated
that intravenously delivered MSCs expressing
TRAIL can home into malignant pleural mesotheli-
oma and can induce apoptosis in cancer cells [13].
MSCs do not normally express endogenous
TRAIL (Figure 1) [47] and, in the present study, we
show that the infection with a lentivirus expressing
GFP does not lead to any detectable endogenous
TRAIL expression (Figure 1). Interestingly, TNF-a
was found to be able to trigger endogenous TRAIL
expression in MSCs [47]. However, TNF-aeinduced
TRAIL expression appeared to only occur within cells
and cells lacked apparent soluble TRAIL release,
which necessitates cell-to-cell contact for apoptotic
activity [47].
TRAIL and other members of the TNF super-
family are type II transmembrane proteins and are
expressed as membrane-bound homotrimeric mole-
cules. It has been demonstrated by others that olig-
omerization is necessary for efﬁcient induction of
apoptosis in target cells. Holler et al. [48] showed
that a hexameric FasL, consisting of two homo-
trimers at close proximity, represents the minimal
ligand complex structure that is required to effec-
tively form the death-inducing signaling complex
and to activate apoptosis. The trimeric FasL failed to
induce a death-inducing signaling complex and is
thus inefﬁcient in triggering apoptosis. A recent
study found that TRAIL proteins expressed by hu-
man syncytiotrophoblasts exist as a hexameric form
on exosome membranes [49]. The particulate
aggregation of ﬂT that we have observed on the cell
surface of MSCs and the higher biological activity of
ﬂT than IZ-fused soluble TRAIL both indicate the
possibility that higher-order oligermization of ﬂT
occurs on the cell membrane of transduced MSCs.
In our construction of soluble TRAIL, we used
an IZ as a trimerization enhancer, which has been
previously shown to facilitate the formation of a
TRAIL homotrimer and to enhance its cytotoxicity
[50]. The IZ-fused sT construct created in this study
conﬁrmed the secretory advantage of the use of IZ
for recombinant soluble TRAIL preparation. How-
ever, we demonstrate that ﬂT is also secreted and is
more efﬁcient in inducing apoptosis in cancer cells
than either rTRAIL produced from bacterial cells or
the trimerized sT secreted by transduced MSCs.
To our knowledge, this is the ﬁrst observation sug-
gesting that mammalian cell-secreted ﬂT is superiorto N-terminal-truncated soluble TRAIL versions
(amino acids 114e281 or amino acids 95e281).
An important observation is that MSC expression
of ﬂT induces apoptosis in cancers that are
completely resistant to recombinant soluble TRAIL.
The reason for this effect is not clear; however, two
recent publications outline that higher-order clus-
tering of TRAIL-Rs may be necessary for full
extrinsic death pathway activation [51,52]. These
studies demonstrate that neither soluble TRAIL nor
antibodies against TRAIL-Rs are capable of higher-
order clustering alone, although they are in combi-
nation. TRAIL expressed on the cell surface may be
able to induce higher-order clustering as a result of
movements permitted by the ﬂuidic nature of the cell
membrane. This might be the reason for the greater
efﬁcacy of MSC-ﬂT than recombinant TRAIL or
MSC-sT in our in vitro studies. It will be interesting
to understand in future studies whether ﬂT but not
sT is capable of this clustering and whether TRAIL
requires cell membrane binding for this full killing
effect.
Soluble recombinant TRAIL has been exten-
sively tested as a cancer therapy in vitro and in human
studies [4,5,53e60]. Completed clinical trials have
used recombinant protein doses of up to 30 mg/kg
[59], possibly because of its short half-life and the
low efﬁciency of the recombinant soluble ligand.
However, therapeutic beneﬁts have been limited [9].
The clinical failure of recombinant soluble TRAIL
has mainly been attributed to cancer cell resistance
[9]. MSC delivery of full-length TRAIL not only
results in the delivery of stably expressed TRAIL but
also overcomes at least some of the resistance.
In the present study, we have therefore validated
cell infection, target gene expression and gene func-
tion through the use of our clinically approved lenti-
viral backbone with the constitutive CMV promoter.
We show that transduction with this virus does not
adversely affect cell phenotype and we clearly
demonstrate that the cancer cell-killing function of
full-length TRAIL is superior to that of the shortened
soluble form of TRAIL. In further studies, it will be
interesting to delineate whether this improved func-
tion of full-length TRAIL is due to higher order
clustering. Importantly, we also show that MSC-ﬂT
cells are capable of partially overcoming cancer cell
TRAIL resistance and that they hold promise for the
treatment of diverse cancer types.Acknowledgments
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